{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:50:46Z","timestamp":1782730246212,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T00:00:00Z","timestamp":1397174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00417-014-2624-4","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T01:08:10Z","timestamp":1397092090000},"page":"1573-1579","source":"Crossref","is-referenced-by-count":16,"title":["Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration"],"prefix":"10.1007","volume":"252","author":[{"given":"Tae Gon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"2624_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"2624_CR2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"2624_CR3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00006982-200604000-00001","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390","journal-title":"Retina"},{"key":"2624_CR4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583","journal-title":"Am J Ophthalmol"},{"key":"2624_CR5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908","journal-title":"N Engl J Med"},{"key":"2624_CR6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jcrs.2011.10.036","volume":"38","author":"H Tabandeh","year":"2012","unstructured":"Tabandeh H, Chaudhry NA, Boyer DS, Kon-Jara VA, Flynn HW Jr (2012) Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. J Cataract Refract Surg 38:677\u2013682","journal-title":"J Cataract Refract Surg"},{"key":"2624_CR7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5301\/EJO.2011.6389","volume":"21","author":"M Muzyka-Wozniak","year":"2011","unstructured":"Muzyka-Wozniak M (2011) Phacoemulsification in eyes with neovascular AMD treated with anti-VEGF injections. Eur J Ophthalmol 21:766\u2013770","journal-title":"Eur J Ophthalmol"},{"key":"2624_CR8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ajo.2011.04.025","volume":"152","author":"PJ Rosenfeld","year":"2011","unstructured":"Rosenfeld PJ, Shapiro H, Ehrlich JS, Wong P (2011) Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials. Am J Ophthalmol 152:793\u2013798","journal-title":"Am J Ophthalmol"},{"key":"2624_CR9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.eye.6703053","volume":"23","author":"L Arias","year":"2009","unstructured":"Arias L, Armada F, Donate J, Garcia-Arumi J, Giralt J, Pazos B, Pinero A, Martinez F, Mondejar JJ, Ortega I, Zlateva G, Buggage R (2009) Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye (Lond) 23:326\u2013333","journal-title":"Eye (Lond)"},{"key":"2624_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0008-4182(05)80074-2","volume":"40","author":"A Oliver-Fernandez","year":"2005","unstructured":"Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S (2005) Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 40:313\u2013319","journal-title":"Can J Ophthalmol"},{"key":"2624_CR11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/IAE.0b013e3182018df6","volume":"32","author":"R Rauch","year":"2012","unstructured":"Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV (2012) Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 32:1260\u20131264","journal-title":"Retina"},{"key":"2624_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00417-012-2038-0","volume":"251","author":"PS Muether","year":"2013","unstructured":"Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453\u2013458","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2624_CR13","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00417-013-2284-9","volume":"251","author":"M Saleh","year":"2013","unstructured":"Saleh M, Kheliouen M, Tebeanu E, Ballonzoli L, Bourcier T, Speeg-Schatz C, Gaucher D (2013) Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. Graefes Arch Clin Exp Ophthalmol 251:1901\u20131907","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2624_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000353868","volume":"230","author":"R Muniraju","year":"2013","unstructured":"Muniraju R, Ramu J, Sivaprasad S (2013) Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmologica 230:27\u201333","journal-title":"Ophthalmologica"},{"key":"2624_CR15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43\u201358","journal-title":"Am J Ophthalmol"},{"key":"2624_CR16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/bjophthalmol-2012-302995","volume":"97","author":"L Ersoy","year":"2013","unstructured":"Ersoy L, Caramoy A, Ristau T, Kirchhof B, Fauser S (2013) Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery. Br J Ophthalmol 97:862\u2013865","journal-title":"Br J Ophthalmol"},{"key":"2624_CR17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0886-3350(97)80256-8","volume":"23","author":"JL Alio","year":"1997","unstructured":"Alio JL, Sayans JA, Chipont E (1997) Flare-cell meter measurement of inflammation after uneventful cataract surgery with intraocular lens implantation. J Cataract Refract Surg 23:935\u2013939","journal-title":"J Cataract Refract Surg"},{"key":"2624_CR18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399\u20131411","journal-title":"Ophthalmology"},{"key":"2624_CR19","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2624-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-014-2624-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2624-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:40Z","timestamp":1559058040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-014-2624-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2624"],"URL":"https:\/\/doi.org\/10.1007\/s00417-014-2624-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]}}}